Nimenrix (MenACWY-TT) / Pfizer - LARVOL DELTA

Real-World Strains, Real-World Protection: Meningococcal ACWY Conjugate Vaccine (MenACWY-TT) Demonstrates Robust Immunogenicity Against Circulating Hypervirulent Serogroup Y ST-1466 (IDWeek 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Meningococcal Infections

Exploring Superiority of MenACWY-TT Vaccine Compared to MenACWY-CRM Vaccine in Adolescents – a Post-hoc Analysis. (IDWeek 2026) - No abstract available

Head-to-Head • Retrospective data • Infectious Disease

Adult immunization. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Hepatitis B • Herpes Zoster • Infectious Disease • Inflammation • Influenza • Measles • Meningococcal Infections • Pertussis • Pneumococcal Infections • Respiratory Diseases • Respiratory Syncytial Virus Infections • Tetanus • Varicella Zoster

mRNA-1365-P101: A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months (clinicaltrials.gov) - P1 | N=186 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Sep 2026 ➔ Aug 2029 | Trial primary completion date: Aug 2026 ➔ Aug 2029

Trial completion date • Trial primary completion date • Respiratory Diseases

Immunogenicity and safety of a pentavalent meningococcal MenABCWY vaccine in healthy adolescents and young adults: a phase 3, multicountry, randomised, observer-blinded, active-controlled non-inferiority trial. (PubMed, Lancet Child Adolesc Health) - P3 | "The immunological non-inferiority and safety profile of a two-dose MenABCWY series (months 0 and 6) compared with three separate injections of MenB-fHbp (months 0 and 6) and MenACWY-CRM (month 0) for protection against MenA, MenB, MenC, MenW, and MenY indicate that MenABCWY could simplify the vaccination strategy against invasive meningococcal disease through fewer injections, potentially increasing vaccination rates among adolescents and young adults."

Head-to-Head • Journal • P3 data • Infectious Disease • Meningococcal Infections

Podcast: Immune Persistence After Primary Vaccination with MenQuadfi. (PubMed, Infect Dis Ther) - "Several quadrivalent conjugate vaccines (MenACWY), MenQuadfi®, Menveo®, and Nimenrix®, are available, which target the same four serogroups, but differ in antigen composition and carrier proteins. Overall, the evidence supports the use of MenQuadfi as a MenACWY option, including for children, to help provide and maintain protection against IMD in the years following primary vaccination.Podcast available for this article. Supplementary material 1 (MP2 156850 kb)."

Journal • Review • CNS Disorders • Infectious Disease • Meningococcal Infections • Otorhinolaryngology

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (clinicaltrials.gov) - P2 | N=537 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease

A Multicenter trial to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Healthy Children (clinicaltrialsregister.eu) - P2 | N=300 | Sponsor: Valneva Austria GmbH

New P2 trial • Chikungunya • Infectious Disease

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers (clinicaltrials.gov) - P3 | N=840 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections

Live-attenuated chikungunya vaccine in children: a randomized phase 2 trial. (PubMed, Nat Med) - P2 | "Participants (n = 304) received either a half dose (n = 119) or a full dose (n = 124) of VLA1553, or active control meningococcal vaccine (Nimenrix) (n = 61). The trial met its prespecified endpoints and supported the selection of full-dose VLA1553 in future clinical trials in this population, addressing a critical unmet medical need. ClinicalTrials.gov registration: NCT06106581 ."

Journal • P2 data • Chikungunya • Infectious Disease • Meningococcal Infections • Pain

Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (clinicaltrials.gov) - P1/2 | N=750 | Active, not recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections • Pediatrics

Sustained salivary IgG but short-lived IgA responses following primary and booster MenACWY-TT vaccination in older adults. (PubMed, Hum Vaccin Immunother) - "Strong correlations were observed between post-vaccination salivary and serum IgG concentrations, and between salivary IgA and secretory component levels, suggesting systemic origin of IgG and mucosal origin of IgA. These findings highlight that MenACWY-TT vaccination induces durable salivary IgG and transient IgA responses in older adults, with limited enhancement of mucosal IgA after booster vaccination."

Journal • Infectious Disease • Meningococcal Infections

Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025. (PubMed, MMWR Morb Mortal Wkly Rep) - "Two quadrivalent (serogroups A, C, W, and Y) meningococcal conjugate vaccines (MenACWY) (MenACWY-CRM [Menveo, GSK] and MenACWY-TT [MenQuadfi, Sanofi Pasteur]) and two serogroup B meningococcal vaccines (MenB) (MenB-4C [Bexsero, GSK] and MenB-FHbp [Trumenba, Pfizer]) are licensed for use in the United States and recommended by CDC's Advisory Committee on Immunization Practices (ACIP)...On February 14, 2025, the Food and Drug Administration licensed a second pentavalent MenABCWY vaccine (MenACWY-CRM/MenB-4C [Penmenvy, GSK]) for prevention of invasive disease caused by N. meningitidis serogroups A, B, C, W, and Y in persons aged 10-25 years, the same indication for which MenACWY-TT/MenB-FHbp is licensed...Different manufacturers' serogroup B-targeting vaccines are not interchangeable; therefore, when MenACWY-CRM/MenB-4C is used, MenB-4C should be used for the other MenB doses. This report summarizes evidence considered for these recommendations and provides clinical..."

Clinical guideline • Journal • Immunology • Infectious Disease • Meningococcal Infections • Primary Immunodeficiency

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (clinicaltrials.gov) - P4 | N=125 | Recruiting | Sponsor: Emory University | Not yet recruiting ➔ Recruiting

Enrollment open

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (clinicaltrials.gov) - P2 | N=537 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P2 trial • Infectious Disease

Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers (clinicaltrials.gov) - P3 | N=840 | Completed | Sponsor: Sanofi Pasteur, a Sanofi Company | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections

Chikungunya: Dose-Response Phase 2 Safety and Immunogenicity Month 6 Data of VLA1553, a Single-Dose Live-Attenuated Vaccine in Children Aged 1 to 11 Years (ASTMH 2025) - P2 | "Among the 304 healthy children randomized 2:2:1 to a single shot of either the half or full dose VLA1553 formulation or control (Nimenrix®, tetravalent meningococcal vaccine), 7.9% had pre-existing CHIKV-specific antibodies. The Month 6 data confirm that the safety and tolerability profile was highly similar for VLA1553 full and half dose. The more pronounced immune response of the full compared to the half dose supports the use of the full dose moving forward."

Clinical • Late-breaking abstract • P2 data • Chikungunya • Infectious Disease • Meningococcal Infections

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults (clinicaltrials.gov) - P4 | N=125 | Not yet recruiting | Sponsor: Emory University

New P4 trial

Investigating a Vaccine Against COVID-19 (clinicaltrials.gov) - P2/3 | N=10811 | Completed | Sponsor: University of Oxford | Active, not recruiting ➔ Completed | Trial completion date: Mar 2024 ➔ Feb 2025 | Trial primary completion date: Mar 2024 ➔ Feb 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

mRNA-1365-P101: A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months (clinicaltrials.gov) - P1 | N=186 | Active, not recruiting | Sponsor: ModernaTX, Inc. | N=310 ➔ 186

Enrollment change • Respiratory Diseases

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial. (PubMed, Infect Dis Ther) - P3 | "Consideration of all immunogenicity and safety data generated in this study supports the incorporation of MenACYW-TT into the routine childhood vaccination schedule as a 2 + 1 regimen starting at age 6 weeks."

Journal • CNS Disorders • Infectious Disease • Meningococcal Infections • Pediatrics • Pneumococcal Infections

Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain. (PubMed, Vaccines (Basel)) - "When strategies included a two-dose infant schedule, the earlier the infant MenACWY-TT vaccine was administered, the more additional cases, deaths, and cases with LTS were prevented (base-case and high-incidence scenarios). This analysis supports implementation of MenACWY-TT as a replacement for MenC vaccination."

Journal • Infectious Disease • Meningococcal Infections • Pediatrics • Tetanus

A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT). (PubMed, Hum Vaccin Immunother) - "Real-world studies show high vaccine effectiveness and herd protection benefits. However, further research is needed to evaluate long-term immunity and efficacy in high-risk populations."

Journal • Review • Infectious Disease • Meningococcal Infections • Tetanus

Immunogenicity of primary and booster MenACWY-TT vaccination in older adults and the importance of IgM. (PubMed, NPJ Vaccines) - "Interestingly, IgM depletion markedly reduced rSBA titers, while IgG depletion had minimal impact. These findings highlight that MenACWY-TT vaccination elicits functional antibody responses in older adults, largely driven by IgM."

Clinical • Journal • Infectious Disease • Meningococcal Infections

A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants (clinicaltrials.gov) - P2 | N=724 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Meningococcal Infections